CoChat

Systemic immune‐checkpoint blockade with anti‐PD1 antibodies does not alter cerebral amyloid‐β burden in several amyloid transgenic mouse models

Latta‐Mahieu, Martine, Elmer, Bradford, Bretteville, Alexis, Wang, Yaming, Lopez‐Grancha, Mati, Goniot, Philippe, Moindrot, Nicolas, Ferrari, Paul, Blanc, Véronique, Schussler, Nathalie, Brault, Emmanuel, Roudières, Valérie, Blanchard, Véronique, Yang, Zhi‐Yong, Barneoud, Pascal, Bertrand, Philippe, Roucourt, Bart, Carmans, Sofie, Bottelbergs, Astrid, Mertens, Liesbeth, Wintmolders, Cindy, Larsen, Peter, Hersley, Caroline, McGathey, Tyler, Racke, Margaret M., Liu, Ling, Lu, Jirong, O'Neill, Michael J., Riddell, David R., Ebneth, Andreas, Nabel, Gary J., Pradier, Laurent · 2018 · Glia
Cited by 64

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Chronic inflammation represents a central component in the pathogenesis of Alzheimer's disease (AD). Recent work suggests that breaking immune tolerance by Programmed cell Death‐1 (PD1) checkpoint inhibition produces an IFN‐γ‐dependent systemic immune response, with infiltration of the brain by peripheral myeloid cells and neuropathological as well as functional improvements even in mice with advanced amyloid pathology (Baruch et al., (): Nature Medicine, 22:135–137). Immune checkpoint inhibition was therefore suggested as potential treatment for neurodegenerative disorders when activation of the immune system is appropriate. Because a xenogeneic rat antibody (mAb) was used in the study, whether the effect was specific to PD1 target engagement was uncertain. In the present study we examined whether PD1 immunotherapy can lower amyloid‐β pathology in a range of different amyloid transgenic models performed at three pharmaceutical companies with the exact same anti‐PD1 isotype and two mouse chimeric variants. Although PD1 immunotherapy stimulated systemic activation of the peripheral immune system, monocyte‐derived macrophage infiltration into the brain was not detected, and progression of brain amyloid pathology was not altered. Similar negative results of the effect of PD1 immunotherapy on amyloid brain pathology were obtained in two additional models in two separate institutions. These results show that inhibition of PD1 checkpoint signaling by itself is not sufficient to reduce amyloid pathology and that additional factors might have contributed to previously published results (Baruch et al., (): Nature Medicine, 22:135–137). Until such factors are elucidated, animal model data do not support further evaluation of PD1 checkpoint inhibition as a therapeutic modality for Alzheimer's disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/glia.23260

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 64

Metadata

Authors
Latta‐Mahieu, M., Elmer, B., Bretteville, A., Wang, Y., Lopez‐Grancha, M., Goniot, P., Moindrot, N., Ferrari, P., Blanc, V., Schussler, N., Brault, E., Roudières, V., Blanchard, V., Yang, Z., Barneoud, P., Bertrand, P., Roucourt, B., Carmans, S., Bottelbergs, A., Mertens, L., Wintmolders, C., Larsen, P., Hersley, C., McGathey, T., Racke, M. M., Liu, L., Lu, J., O'Neill, M. J., Riddell, D. R., Ebneth, A., Nabel, G. J., & Pradier, L.
Venue
Glia
Publisher
Wiley
Published
2017-11-14
Volume
66
Issue
3
Pages
492-504
ISSN
  • 0894-1491 (ISSN-L)
  • 1098-1136
OpenAlex
W2770984357
Cited by
64
References
14
FWCI
4.29
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Systemic immune‐checkpoint blockade with anti‐PD1 antibodies does not alter cerebral amyloid‐β burden in several amyloid transgenic mouse models. https://app.cochat.ai/papers/10.1002/glia.23260
The paper
Latta‐Mahieu, M., Elmer, B., Bretteville, A., Wang, Y., Lopez‐Grancha, M., Goniot, P., Moindrot, N., Ferrari, P., Blanc, V., Schussler, N., Brault, E., Roudières, V., Blanchard, V., Yang, Z., Barneoud, P., Bertrand, P., Roucourt, B., Carmans, S., Bottelbergs, A., . . . Pradier, L. (2018). Systemic immune‐checkpoint blockade with anti‐PD1 antibodies does not alter cerebral amyloid‐β burden in several amyloid transgenic mouse models. Glia. https://doi.org/10.1002/glia.23260

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.